European studies have shown sustained IOP reduction, lower medication needs and minimal safety events for at least eight years post-procedure1, including:
35% median
intraocular pressure
reduction (with cataract,
1-8 year studies)1
Mid-teens end-IOP1
Significant
medication reduction
across a broad range
of patients1
Low adverse
event rate (self-limited,
non-sight-threatening)1
We partner with leaders in glaucoma patient care, technology, and research. View our Medical Advisory Board.
1. Durr GM, Töteberg-Harms M, Lewis R, Fea A, Marolo P, Ahmed IK, Current Review of Excimer Laser Trabeculostomy. Eye and Vis 7, 24 (2020).